Characterizing the post-market safety profile of lazertinib: a pharmacovigilance study of the FDA Adverse Events Reporting System Database

Investigational New Drugs 2026

View at publisher
Authors: Connor Frey
DOI: 10.1007/s10637-026-01630-2
Cited by: 1
References: 13

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Pharmacovigilance and Adverse Drug Reactions Colorectal Cancer Treatments and Studies

Publication details

Journal / source
Investigational New Drugs
Publisher
Springer Science and Business Media LLC
Publication date
10 July 2026
Language
EN